GEN lists the top five performing biotech stocks of 2025 and the five biotech stocks that fell the most during this past year, with brief explanations for the increases or declines.

Lucid Motors has launched its "Lucid Recharged" CPO program. This article explores why certified pre-owned options are vital ...

Nike, Inc. stock shows limited upside as FQ2 results reveal mixed signals. Click for this updated look at NKE and where it may be headed in 2026.

Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival ...

PERSEUS trial findings suggest that modern myeloma therapies could lead to survival rates similar to age-matched controls. KLN-1010, an off-the-shelf gene therapy, demonstrated promising MRD-negative ...

In this study, researchers aimed to determine whether Ki67 and TILs in residual breast tumors were prognostic for survival in patients with triple-negative breast cancer who received neoadjuvant ...

Market forecasters project the CAR-T cell therapy market will surge from $3.87 billion in 2024 to $13.25 billion by 2030, driven by unprecedented efficacy in relapsed and refractory patient ...

Natera (NTRA) announced the publication of findings from the randomized, phase III CALGB/SWOG 80702 study in JAMA Oncology. This publication ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

BillionToOne, Inc. Class A (($BLLN)) has held its Q3 earnings call. Read on for the main highlights of the call. BillionToOne’s inaugural earnings ...

The company has developed a method to detect circulating tumor DNA in surgical drain fluid from postoperative patients to detect molecular residual disease.